Press Releases

Freenome Raises $254 Million in New Funding to Accelerate its Platform for Early Cancer Detection
–  Roche led the financing alongside existing and new investors – – The funds will progress clinical programs and expand platform capabilities – SOUTH SAN ...
Freenome Initiates PROACT LUNG Clinical Study for the Early Detection of Lung Cancer Using Blood Test Developed on Multiomics Platform
– Registrational study targets enrollment of 20,000 individuals at high risk of lung cancer SOUTH SAN FRANCISCO, CA (Dec. 12, 2023) — Freenome, a privately ...
Walgreens and Freenome Establish Partnership to Increase Diversity in Research for the Early Detection of Cancer
DEERFIELD, Ill. & SAN FRANCISCO, June 15, 2023 — Walgreens and Freenome today announced a multi-year relationship to advance clinical studies of Freenome’s blood-based tests for ...
Freenome Acquires Global Immunodiagnostics Developer Oncimmune Ltd
– Acquisition enhances Freenome’s product portfolio, including autoantibody platform with additional biomarkers important in cancer detection – Freenome continues growth trajectory toward offering multiple cancer ...
Freenome Adds University of Chicago as a Partner for its Vallania Study
– The Vallania Study targets multiple cancers with different care pathways – University of Chicago to enroll patients across its diverse network, expanding access to ...
Freenome Adds Renown Health as Partner for The Sanderson Study
– The Sanderson Study is Freenome’s study that pairs real-world data with multiomics for the detection of multiple cancers – Renown Health’s William N. Pennington ...
Freenome Presents a Subject Population Analysis of a Clinical Study Using a Multiomics Blood Test for the Early Detection of Colorectal Cancer
– PREEMPT CRC is a large, representative registrational study for the early detection of colorectal cancer – Findings presented at the Western Colorectal Cancer Consortium Conference ...
Freenome Partners with Geisinger for the Sanderson Study
– The Sanderson Study is Freenome’s clinical study that combines multiomics with real-world data to detect multiple cancers  – Geisinger to enroll patients across its network, ...
Freenome Presents Research Highlighting the Promise of Identifying Drug-Response Biomarker for DLBCL Patients
Freenome’s comprehensive multiomics and multi-feature computational approach provides insights for therapy development and patient efficacy SOUTH SAN FRANCISCO, Dec. 12, 2022 — Freenome, a privately ...
Freenome Adds Several Community Partners to Clinical Study for the Early Detection of Cancer
– Community-based research ensures broad reach, diversity – The Vallania Study targets cancers with significant unmet needs and different care pathways SOUTH SAN FRANCISCO, Nov. 1, ...
Freenome Launches Study of Multiple Cancers Pairing Multiomics with Real-World Data
– The company is pioneering a new approach for the development and improvement of its test platform by combining multiomics with real-world data  – The Sanderson ...
Freenome Continues Growth, Adds Three New Leaders
Sally Howard, Charles Mwangi, and Julie Tran join the company to lead regulatory, finance, and people teams SOUTH SAN FRANCISCO  —  Freenome, a privately held ...
Freenome Research Underscores Clinical Utility of Screening Tests That Detect Adenomas
Research finds adenoma detection reduces mortality in colorectal cancer regardless of adherence and implementation scenarios SOUTH SAN FRANCISCO, May 25, 2022 — Freenome, a privately held ...
Freenome and Morehouse Present Research on Study Participation Among Black Patients
– Study finds recruitment of Black patients at a Historically Black College or University (HBCU) matches other study sites – Study receives Poster of Distinction ...
Largest Clinical Study Validating a Blood-based Colorectal Screening Test Completes Enrollment
– PREEMPT CRC is Freenome’s registrational study to validate its test for the early detection of cancer – More than 35,000 participants enrolled and completed with a ...